Drug Trial Radar · NCT03744468
Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
147
Actual
Start
Nov 13, 2018
Primary completion
Feb 6, 2025
Study completion Feb 6, 2025
Sponsor
- Lead sponsor
- BeiGeneBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Nov 16, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was an open-label, multicenter, nonrandomized Phase 1 and 2 clinical trial evaluating various combinations of surzebiclimab (BGB-A425) and/or alcestobart (LBL-007) with tislelizumab.
Conditions
- Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in
- HNSCC for Phase 2 Dose Expansion
- NSCLC for Phase 2 Dose Expansion
Interventions
SurzebiclimabDrug
Humanized immunoglobulin G1 (IgG1)-variant monoclonal antibody against TIM-3
TislelizumabDrug
Humanized, IgG4-variant monoclonal antibody against PD-1
AlcestobartDrug
Human anti LAG-3 antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Up to 30 days after last dose of study drug (maximum treatment duration: up to 32.7 months)
- Phase 1: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of Surzebiclimab in Combination With TislelizumabTime frame: Up to 28 days
- Phase 1: Recommended Phase 2 Dose (RP2D) of Surzebiclimab in Combination With TislelizumabTime frame: Up to 28 days
- Phase 2 (Safety Lead-In): Number of Participants With TEAEs and SAEsTime frame: Up to 30 days after last dose of study drug (maximum duration of treatment: up to 19.6 months in Cohort A and up to 21.5 months in Cohort B)
- Phase 2 (Safety Lead-In): MTD or MAD of Alcestobart in Combination With TislelizumabTime frame: Up to 21 days
- Phase 2 (Safety Lead-In): MTD or MAD of Alcestobart in Combination With Surzebiclimab and TislelizumabTime frame: Up to 21 days
- Phase 2 (Safety Lead-In): RP2D of Alcestobart in Combination With Surzebiclimab and TislelizumabTime frame: Up to 21 days
- Phase 2 (Dose Expansion): Overall Response Rate (ORR)Time frame: Maximum time on study: Cohort 1: up to 31.3 months, Cohort 2: up to 32.0 months, Cohort 4: up to11.3 months, Cohort 5: up to 15.9 months
Locations
40 sites in 6 countries. Site status is shown where the registry gives one.
Chao Family Comprehensive Cancer Center
Orange, California
University of Colorado Cancer Center
Aurora, Colorado
University of Chicago Medical Center
Chicago, Illinois
University of Kentucky Markey Cancer Center
Lexington, Kentucky
Weill Cornell Medical College Newyork Presbyterian Hospital
New York, New York
University of North Carolina At Chapel Hill
Chapel Hill, North Carolina
Fox Chase Cancer Center
Philadelphia, Pennsylvania
The University of Texas Md Anderson Cancer Center
Houston, Texas
Ut Health San Antonio Mays Cancer Center
San Antonio, Texas
University of Virginia
Charlottesville, Virginia
Schar Cancer Institute
Fairfax, Virginia
Sydney Southwest Private Hospital
Liverpool, New South Wales, Australia
Sunshine Coast Hospital and Health Service
Birtinya, Queensland, Australia
Gold Coast University Hospital
Southport, Queensland, Australia
Lyell McEwin Hospital
Elizabeth Vale, South Australia, Australia
Calvary North Adelaide Hospital
North Adelaide, South Australia, Australia
Box Hill Hospital
Box Hill, Victoria, Australia
Cabrini Research and Education Institute
Malvern, Victoria, Australia
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia
Western Health Sunshine Hospital
St Albans, Victoria, Australia
Hollywood Private Hospital
Nedlands, Western Australia, Australia
Linear Clinical Research
Nedlands, Western Australia, Australia
Centre de Lutte Contre Le Cancer Institut Bergonie
Bordeaux, France
Centre de Lutte Contre Le Cancer Francois Baclesse
Caen, France
Institut Curie Paris
Paris, France
Irccs Azienda Ospedaliero Universitaria Bologna
Bologna, Italy
Fondazione Irccs Istituto Nazionale Dei Tumori
Milan, Italy
Istituto Di Candiolo Irccs
Torino, Italy
Ajou University Hospital
Suwon, South Korea
Chungbuk National University Hospital
SeowonGu CheongjuSi, Chungcheongbukdo, South Korea
The Catholic University of Korea, St Vincents Hospital
PaldalGu SuwonSi, Gyeonggi-do, South Korea
Gachon University Gil Medical Center
NamdongGu, Incheon Gwang'Yeogsi, South Korea
The Catholic University of Korea, Seoul St Marys Hospital
SeochoGu, Seoul Teugbyeolsi, South Korea
Severance Hospital Yonsei University Health System
SeodaemunGu, Seoul Teugbyeolsi, South Korea
Asan Medical Center
SongpaGu, Seoul Teugbyeolsi, South Korea
Ulsan University Hospital
Donggu, Ulsan Gwang'Yeogsi, South Korea
Institut Catala Doncologia
Barcelona, Spain
Hospital Clinico San Carlos
Madrid, Spain
Hospital Universitario Hm Madrid Sanchinarro
Madrid, Spain
Hospital Universitario Virgen Del Rocio
Seville, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.